Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Needham & Company LLC reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

Several other brokerages also recently weighed in on TSHA. Chardan Capital reiterated a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. JMP Securities reiterated a market outperform rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. BMO Capital Markets assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They issued an outperform rating and a $5.00 target price for the company. Finally, Jefferies Financial Group reiterated a buy rating and set a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of Buy and a consensus target price of $6.60.

Taysha Gene Therapies Stock Up 1.3 %

Shares of NASDAQ:TSHA opened at $2.27 on Tuesday. Taysha Gene Therapies has a 1-year low of $0.62 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The stock has a market cap of $424.54 million, a P/E ratio of -4.63 and a beta of 0.41. The firm has a fifty day moving average price of $2.87 and a 200 day moving average price of $2.49.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same period in the prior year, the company earned ($0.28) earnings per share. Sell-side analysts predict that Taysha Gene Therapies will post -0.41 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning purchased 1,333,333 shares of the firm’s stock in a transaction dated Thursday, June 27th. The shares were acquired at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of TSHA. Howard Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth $25,000. Victory Capital Management Inc. purchased a new position in Taysha Gene Therapies during the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd acquired a new position in Taysha Gene Therapies during the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $38,000. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies in the first quarter valued at approximately $69,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.